Log in
Forgot password ?
Become a member for free
Sign up
Sign up
Dynamic quotes 

4-Traders Homepage  >  Equities  >  Nyse  >  Pfizer Inc       

Mes dernières consult.
Most popular
News SummaryMost relevantAll newsSector newsTweets
Latest news on PFIZER INC
06:32p Pfizer announces new $10 billion share buyback, hikes dividend
06:18pDJPFIZER : Raises Dividend 6%, Sets New $10 Billion Buyback Program
05:45p PFIZER : Declares First-Quarter 2018 Dividend
04:21p DOW MOVERS : Dis, axp
03:15p PFIZER : Announces fda approval of xeljanz and xeljanz xr for the treatment of a..
03:15p PFIZER : Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Developm..
03:15p PFIZER : Announces pricing terms of private exchange offer for its 6.500 per cen..
08:06a Stocks mostly up
12/16 PFIZER : US regulators approve Pfizers Remicade biosimilar
12/16 PFIZER : weighs `strategic options` for newly FDA-approved Remicade biosim, its ..
12/15 DOW MOVERS : Ibm, pfe
12/15 PFIZER INC. : Announces Expiration and Results of its Private Exchange Offer for..
12/15 PFIZER : Kirsten Lund-Jurgensen Named to Executive Committee of Manufacturers As..
12/15 PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ (Tofa..
12/15 Germany's Merck in fresh bid to enter U.S. MS pill market
12/15 PFIZER : `No plans to launch second approved Remicade biosimilar in US`
12/15 PFIZER : Fda approves new pfizer biosimilar
12/15 PFIZER : Preliminary Data from Servier and Pfizer's UCART19 Product Candidate Sh..
12/15 PFIZER : Phase 3 trumenba data published in new england journal of medicine demo..
12/15 PFIZER INC. (LON : PFZ) Files An 8-K Financial Statements and Exhibits
12/15 PFIZER : Announces FDA Approval of XELJANZ® (tofacitinib) and XELJANZ® XR for th..
12/14 PFIZER INC : Other Events, Financial Statements and Exhibits (form 8-K)
12/14 PFIZER : Researchers' Work from Pfizer Focuses on Carboxylic Ester Hydrolases (A..
12/14 PFIZER INC. : Announces i Private Exchange Offer for its 6.500 per cent. Notes d..
12/14 SPARK THERAPEUTICS : and Pfizer announce publication in The New England Journal ..
12/14 PFIZER : New Proteins and Peptides Study Findings Recently Were Reported by Rese..
12/14 PFIZER : Updated Data from Phase 3 Trial of IBRANCE® palbociclib Plus Letrozole ..
12/14 PFIZER : Reports Findings in Pharmacology (Pharmacology in translation; the prec..
12/14 PFIZER INC. : Announces Pricing Terms of Private Exchange Offer for its 6.500 pe..
12/14 PFIZER : U.S. Food and Drug Administration Extends Action Date for XELJANZ Suppl..
12/14 CELLECTIS : - Preliminary Data from Servier and Pfizer's UCART19 Product Candida..
12/14 PFIZER : Initiates Phase 3 Program for PF-04965842, a JAK1 Inhibitor in Developm..
12/14 SMI’S ADC CONFERENCE : Exclusive Pfizer Speaker Interview Released
12/14 ABOUT LAST WEEK : Casino pushes back against unionization, Pfizer wants lethal d..
12/14 PFIZER : FDA Approves New Pfizer Biosimilar
12/13 PFIZER : Phase 3 TRUMENBA® (Meningococcal Group B Vaccine) Data Published in New..
12/13 SPARK THERAPEUTICS : and Pfizer Announce Longer-term Preliminary Data Showing Co..
12/13 PFIZER : Commissioners approve nearly $1.5 million incentive for Pfizer
12/13 PFIZER : U.S. Food and Drug Administration Extends Action Date for XELJANZ (Tofa..
12/13 MYRIAD GENETICS : Myriads BRACAnalysis CDx Test Effectively Identified Metastati..
12/12 PFIZER : U.S. Food And Drug Administration Extends Action Date For XELJANZ® (Tof..
12/12 Sanofi investors hungry for drug progress and deal news
12/12 PROTEOSTASIS THERAPEUTICS, INC. (NAS : PTI) Files An 8-K Departure of Directors ..
12/12 SPARK THERAPEUTICS : Pfizer Record Sustained Factor IX Activity Levels In SPK-90..
12/11 PFIZER : summit strengthens fight against pneumonia, meningitis
12/11 Stocks mixed bag
12/11 PFIZER : Big pharma's blockbuster tax cuts
12/11 FRANK CLEMENTE : Big Pharma's blockbuster tax cuts
12/10 PFIZER : Albany Advocacy Resource Center to host several holiday events
12/10 PFIZER : Townsfolk near Viagra factory talk of 'love fumes,' but Pfizer says tha..
12/09 PFIZER : Talazoparib Significantly Extends PFS in Phase III Embraca Trial of Pat..
12/09 SPARK THERAPEUTICS : 1-year data set Spark/Pfizer on track with hemophilia B gen..
12/09 PFIZER : Generic Viagra to hit the market
12/08 PFIZER : Turning wood into art
12/08 PFIZER INC. : - Updated Data from Phase 3 Trial of IBRANCE Plus Letrozole in ER+..
12/08 SPARK THERAPEUTICS : and Pfizer Announce Publication in the New England Journal ..
12/08 PFIZER : Talazoparib Significantly Extends Progression-Free Survival in Phase 3 ..
12/08 PFIZER INC. : Announces (i) Private Exchange Offer for Its 6.500 Per Cent
12/08 SPARK THERAPEUTICS : reports bleeding rate data for hemophilia B therapy
12/08 SPARK THERAPEUTICS : and Pfizers gene therapy wows in haemophilia B
12/08 PFIZER : Spark, Pfizer pass another milestone with impressive results treating h..
12/08 PFIZER : Broadway Triangle Deal Could Squeeze Out Families, Says Levin
12/07 PFIZER : Reports from Pfizer Describe Recent Advances in Hormones (Pharmacologic..
12/07 PFIZER : Investigators at Pfizer Report Findings in Tritium (Preparation of trit..
12/07 PFIZER : Studies from Pfizer in the Area of Nitriles Reported (Parallel Synthesi..
12/07 PFIZER : Findings from Pfizer in the Area of Gastrointestinal Agents Described [..
12/07 PFIZER : Researchers at Pfizer Report Findings in Drug Development (Current prac..
12/07 PFIZER : New Pharmacokinetics Study Findings Recently Were Reported by Researche..
12/07 PFIZER : Enters into Agreement to Develop and Commercialize CRESEMBA® isavuconaz..
12/07 PFIZER : Six Researchers Chosen for New Pfizer-NCBiotech Distinguished Postdocto..
12/07 PFIZER : Doctor's notes
12/07 PFIZER INC. (LON : PFZ) Files An 8-K Other Events
12/07 PFIZER INC : Other Events, Financial Statements and Exhibits (form 8-K)
12/07 PFIZER : Clinical Trial Reinforces Benefit Of Pfizer`s Ibrance In Breast Cancer ..
1  2  3  4  5  6  7  8  9  10Next
Financials ($)
Sales 2017 52 550 M
EBIT 2017 19 881 M
Net income 2017 10 958 M
Debt 2017 23 944 M
Yield 2017 3,43%
P/E ratio 2017 19,95
P/E ratio 2018 17,20
EV / Sales 2017 4,68x
EV / Sales 2018 4,54x
Capitalization 222 B
Income Statement Evolution
Mean consensus OUTPERFORM
Number of Analysts 24
Average target price 38,2 $
Spread / Average Target 2,8%
EPS Revisions
Ian C. Read Chairman & Chief Executive Officer
Albert Bourla Chief Operating Officer
Frank A. D'Amelio Chief Financial Officer & EVP-Business Operations
Freda C. Lewis-Hall Chief Medical Officer & Executive Vice President
Mikael Dolsten President-Worldwide Research & Development
Sector and Competitors
1st jan.Capitalization (M$)
JOHNSON & JOHNSON23.65%382 722
PFIZER14.53%221 738
NOVARTIS13.09%221 731
ROCHE HOLDING LTD.4.94%212 270
MERCK AND COMPANY-4.47%153 386